Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Coronavirus information
Coronavirus information
The Zero Canada Project provides resources to help you make the most of staying home.
Visit the hub

A man walks past a sign outside Pfizer Headquarters in New York on July 22.

Carlo Allegri/Reuters

Several major U.S. drugmakers will report second-quarter results this week, with investors eager for fresh details from Pfizer Inc, Merck & Co and others on their efforts to develop vaccines and therapies against the novel coronavirus.

The earnings reports, including from Gilead Sciences Inc - maker of one of the only treatments that has shown a benefit for hospitalized COVID-19 patients - will be closely watched for any developments that could help contain the pandemic, which has claimed some 650,000 lives worldwide and upended economies.

The supply, pricing and profitability for these potential products also will be hot topics for companies reporting this week, including Eli Lilly and Co, which is developing an antibody treatment for the still rapidly-spreading disease.

Story continues below advertisement

Earnings reports are also due from British drugmakers GlaxoSmithKline Plc and AstraZeneca Plc and France’s Sanofi, which are working on vaccines in various stages of development.

Wall Street also will be looking for any signs of weakness in the companies’ big-selling products as the virus runs rampant in many U.S. states, which may stop patients with other conditions from going to hospitals or doctors due to infection fears, as was seen earlier in the U.S. outbreak.

While shares of small vaccine developers have skyrocketed this year over optimism that their success could help end the pandemic, the picture has been more mixed for large U.S. drugmakers. The S&P 500 pharmaceuticals industry index is down about 1% so far this year, against little change for the overall benchmark S&P 500.

Globally, drugmakers are expected to increase second-quarter earnings per share by 2%, after they rose 17% in the first quarter, according to Cowen & Co.

“We are expecting a fairly solid set of results with most core products either not impacted by COVID-19 or recovering faster than expected,” JP Morgan analysts said in note.

Pfizer, which has released early data on its vaccine candidate being developed with German biotech BioNTech SE , will kick off the week of drugmaker earnings on Tuesday morning.

Investors will be looking for more details on the timing of the vaccine’s development after the U.S. government agreed last week to pay nearly $2 billion to buy enough of it to inoculate 50 million people if it proves to be safe and effective.

Story continues below advertisement

Gilead’s antiviral treatment, remdesivir, has become a key weapon for many countries after the intravenously administered medicine helped shorten hospital recovery times in a U.S. trial.

But the drug’s supply has been an issue with cases spiking in much of the United States and elsewhere. Some other countries have voiced concerns over its availability after the U.S. government said in June it had secured nearly all supplies over the next three months.

“We expect they will sell as much as they can make for the next 6-plus months and it will be needed in 2021 as well,” Jefferies analyst Michael Yee said in a note ahead of Gilead’s results on Thursday.

With Merck’s experimental COVID-19 vaccine trailing others in development, its top-selling cancer drug Keytruda will be under scrutiny when the drugmaker reports results on Friday. Brokerages expect the blockbuster immunotherapy to recover after disappointing first-quarter sales.

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies